Taiwan News1mon
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
said Laura Niklason ... or even biologic grafts more successful. I am most excited about the promise that SYMVESS holds for the long-term experience of our patients. I hope that, with SYMVESS, the ...
Nasdaq12d
Humacyte To Submit IND Application For Small-Diameter ATEV In Coronary Bypass Surgery
This innovation could provide a much-needed off-the-shelf alternative to traditional grafts, potentially improving ... of the sdATEV in CABG," said Laura Niklason, Founder and CEO of Humacyte.
Business Insider20d
Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for ... arterial injury,” said Laura Niklason, M.D., Ph.D., Founder and Chief ...
The Globe and Mail1mon
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
said Laura Niklason ... ATEV in the vascular trauma indication was approved by the FDA in December 2024. Preclinical development is also underway in coronary artery bypass grafts, pediatric ...